Clinical trial · Interventional
Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules
The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It has been shown that insulin might be involved in the pathogenesis of thyroid growth. Objective To evaluate the impact of IR and metformin use on the volume of benign thyroid nodules (TNs). Methods A randomized clinical trial to placebo (P) or MTF use. Previous fine needle aspiration confirming the diagnosis is necessary to inclusion. Patients will receive similar tablets of MTF and placebo and instruct to take 3 tablets/day of MTF (500mg/tablet). Thyroid volume, as TN volume, will be assess by ultrasound, both in the beginning, six months and one year after randomization, by the same researcher blinded regarding location group. Blood samples to measure: TSH, FT4, TPO-Ab, lipid profile, glucose and insulin were done after 8h fasting.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulin Resistance | — | UNRESOLVED | — |
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Metformin
- description
- patients randomized to Metformin group
- interventionNames
- Drug: Metformin
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- patients randomized to placebo group
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- changes in nodule volume from baseline after metformin use
- timeFrame
- one year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patients with benign nodules diagnosed by fine needle aspiration biopsy (FNAB) Exclusion Criteria: * Nodules with a predominantly cystic pattern * Eggshell calcification * Coalescent thyroid nodules (not suitable for size analysis) * Pregnancy * Diabetes * Acromegaly * Previous use of MTF, levothyroxine, corticoid or any weight loss medication in the past six months * Hepatic or cardiac insufficiency * Creatinine levels \> 1.4 mg/dL * MTF intolerance doses \< 1.0 gram/day
References
Publications (0)
Data not yet available